Disclosed herein are controlled release (GR e.g. extended release (ER) or prolonged release (PR)) oral dosage formulation comprising an effective amount of Torsemide or a pharmaceutically acceptable salt thereof and at least one sustained release excipient c omprising a polymer wherein the at least one matrix component is selected from the group consisting of: hydroxy prop yl cellulose (HPC) hydroxpropyl methyl cellulose (HPMC) glyceryl behenate and a polyethylene glycol glyceride. Torsemide may be present in the formulation in a range of about 1 wt% to about 20 wt% or about 5 wt% to about 10 wt% and the matrix component is present in the formulation in a range of about 5 wt% to about 50 wt% or about 15 wt% to about 35 wt%. The formulation may further comprise at least one binder lactose talc and magnesium stearate. Methods of making and using the controlled release oral dosage Torsemide formulation are also disclosed. A novel mechanism for Torsemide action in diuresis is further disclosed.
